Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

American Journal of Hematology

Volumn 90, Issue 10, 2015, Pages 910-914

  Mori, Silvia ^a   Vagge, Elisabetta ^a,q   Le Coutre, Philipp ^b   Abruzzese, Elisabetta ^c   Martino, Bruno ^d   Pungolino, Ester ^e   Elena, Chiara ^f,r   Pierri, Ivana ^g   Assouline, Sarit ^h   D'Emilio, Anna ⁱ   Gozzini, Antonella ^j   Giraldo, Pilar ^k   Stagno, Fabio ^l   Iurlo, Alessandra ^m   Luciani, Michela ^a   De Riso, Giulia ^a   Redaelli, Sara ^a   Kim, Dong Wook ⁿ   Pirola, Alessandra ^a   Mezzatesta, Caterina ^a   Petroccione, Anna ^o   Lodolo D'Oria, Agnese ^o   Crivori, Patrizia ^o   Piazza, Rocco ^a   Gambacorti Passerini, Carlo ^a,p   more..

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h MCGILL UNIVERSITY   (Canada)

ⁱ SAN BORTOLO HOSPITAL   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^l UNIVERSITY OF CATANIA   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ The Catholic University of Korea   (South Korea)

^o Nerviano (MI)   (Italy)

^p SAN GERARDO HOSPITAL   (Italy)

^q UNIVERSITY HOSPITAL GIESSEN   (Germany)

^r FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB; INTERFERON; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIGITAL POLYMERASE CHAIN REACTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; CLINICAL TRIAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84942194839     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24120     Document Type: Article

References (26)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
2. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-394.
3. Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-3698.
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
5. Gambacorti-Passerini C, Piazza R. How I treat newly diagnosed chronic myeloid leukemia in 2015. Am J Hematol 2015;90:156-161.
6. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-539.
7. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011;86:610-611.
8. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-561.
9. Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-study IV. J Clin Oncol 2014;32:415-423.
10. Vigano I, Di Giacomo N, Bozzani S, et al. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis. Am J Hematol 2014;89:E184-E187.
11. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080-7085.
12. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.
13. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
14. Goh HG, Kim YJ, Kim DW, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: Implication for intermittent imatinib therapy. Leuk Lymph 2009;50:944-951.
15. Guastafierro S, Falcone U, Celentano M, et al. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. Leuk Res 2009;33:1079-1081.
16. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
17. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424-430.
18. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 2013;122:515-522.
19. Goh HG, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymph 2011;52:896-904.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trial 1996;17:343-346.
22. Yhim HY, Lee NR, Song EK, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 2012;36:689-693.
23. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012;97:903-906.
24. Rea D, Nicolini FE, Tulliez M, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months-on behalf of the French CML group filmc. Blood 2014;124:811
25. Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol 2015;26:185-192.
26. Richter J, Soderlund S, Lubking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: A tyrosine kinase inhibitor withdrawal syndrome?. J Clin Oncol 2014;32:2821-2823.